

9 September 2016

ASX ANNOUNCEMENT

Penthrox receives regulatory approval in the UAE

Medical Developments International Limited (ASX: MVP) is delighted to announce that it has received regulatory approval and the Marketing Authorisation (MA) for the sale of Penthrox in the United Arab Emirates (UAE).

The CEO of MVP, Mr. Sharman said: "Penthrox has been supplied for a number of years into the UAE on a "Named Patient Basis" and is used in many of the major private and public hospitals as well as the major Ambulance services. All of these organisations have gone out of their way to make special purchase orders and comply with complex importation rules so they can access Penthrox. MVP's partner for the UAE, Pharma Solutions expect this Marketing Authorisation approval will significantly open up the market and improve sales in the UAE and other regions."

Mr. Sharman said: "This is a very good achievement for MVP and Penthrox. To obtain Marketing Authorisations in the Middle East is a very difficult task. This achievement validates the investment made in the global regulatory dossier that has been approved in Europe and elsewhere. The Marketing Authorisation in the UAE is the first of several MA's we are pursuing in the Middle East including in Jordan, Iran, Iraq and Saudi Arabia. We hope to obtain a number of these MA's in the coming months."

Chairman of MVP, Mr. David Williams said: "The Middle East represents a very lucrative market for MVP. We have been working on regulatory approvals in this region for many years and the UAE approval is a significant breakthrough for MVP. Because of the non-narcotic, fast acting characteristics of Penthrox, it is an ideal trauma analgesic for the entire region, which is "anti-narcotic" in its approach to treating pain."

Enquiries:

David Williams
Chairman
+61 (0) 414 383 593

John Sharman
Chief Executive Officer
+61 (3) 9547 1888

About Pentrox

Penthrox is a fast onset, non-opioid analgesic indicated for pain relief by self-administration in patients with trauma and those requiring analgesia for surgical procedures. Penthrox has been used safely and effectively for more than 30 years in Australia with excess of 5.0 million units sold. There is growing interest in Penthrox being used in patients undergoing investigatory procedures, as well as operational procedures such as colonoscopy.

About Medical Developments International Ltd

MVP is an Australian company delivering emergency medical solutions dedicated to improving patient outcomes. MVP is a leader in emergency pain relief and respiratory products. The Company manufactures Penthrox®, a fast acting trauma & emergency pain relief product. It is used in Australian Hospitals including Emergency Departments, Australian Ambulance Services, the Australian Defence Forces, Sports Medicine and for analgesia during short surgical procedures such as Dental and Cosmetic surgery as well as in other medical applications. MVP is expanding internationally and manufactures a range of world-leading Asthma respiratory devices.

About Pharma Solutions LLC

Pharma Solutions is a regional specialty pharmaceutical marketing and distribution company which provides an effective partnership platform for pharmaceutical companies keen to venture into the emerging markets of Middle East & North Africa (MENA). Pharma Solutions has operations across thirteen countries in MENA and facilitate in-licensing, commercialization and distribution of FDA, EMA/EU approved innovative pharmaceuticals. Pharma Solutions primary focus is on Oncology, Accident & Emergency, Neurology, Hormonal Therapy, Vaccines. Pharma Solutions has in-house competence in Business Development, Regulatory Affairs, Logistics, Commercial Sales and Marketing.